Prevexxion RN


Marek's disease vaccine (live recombinant)

This medicine is authorised for use in the European Union.


Prevexxion RN is a veterinary vaccine used in one-day-old chicks to prevent death and disease and to reduce lesions caused by Marek’s disease (MD) virus (including very virulent MD virus).

MD is a herpesvirus infection of chickens which can cause paralysis of the wings and legs and tumours in various organs. Chickens become infected at an early age via inhalation of dander (flakes of skin) containing the virus which can remain infectious for several months after being shed from the body. Birds infected with MD virus can be carriers and shedders of the virus for life.

Prevexxion RN contains cells with a live recombinant strain of MD virus, serotype 1 called RN1250 that has been modified to increase its effectiveness and safety.

This EPAR was last updated on 06/05/2021

Authorisation details

Product details
Prevexxion RN
Agency product number
Active substance
Live recombinant Marek’s disease (MD) virus, serotype 1, strain RN1250
International non-proprietary name (INN) or common name
Marek's disease vaccine (live recombinant)
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Boehringer Ingelheim Vetmedica GmbH
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Binger Strasse 173
55216 Ingelheim am Rhein

Product information

04/12/2020 Prevexxion RN - EMEA/V/C/005058 - IB/0001


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Immunologicals for aves

Therapeutic indication

For active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by Marek’s disease (MD) virus (including very virulent MD virus).

Assessment history

How useful was this page?

Add your rating